文献速递药物不良反应与药物警戒

欧洲药物警戒中患者参与最佳实践的影响因素:利益相关者分析

Factors Contributing to Best Practices for Patient Involvement in Pharmacovigilance in Europe: A Stakeholder Analysis.
PubMed 文献 · Drug Saf · 2022-08-25

本研究通过文献回顾与20名来自患者组织、制药行业和监管机构的代表访谈,采用反思性主题分析,识别出促进药物警戒中患者参与最佳实践的因素,并基于所有利益相关者意见构建了患者参与的定义,强调患者在决策各层面作为平等伙伴参与。

要点

  • 最佳实践包括从开始即参与、面对面沟通、完整反馈闭环、同级伙伴、结构化参与和指南、建立共同目标、患者教育与赋权、建立信任与平衡。
  • 患者参与定义反映所有类型患者在决策过程所有层面的参与。
  • 患者渴望成为平等伙伴并像其他利益相关者一样轻松参与。

核心结论

  • 基于定性访谈构建了患者参与的定义,识别出跨利益相关者群体提及的促进药物警戒中患者参与最佳实践的因素。

研究设计与样本

  • 定性多利益相关者研究,先进行文献回顾以绘制研究领域并制定访谈指南,随后邀请患者代表、制药行业成员和监管者参与访谈,共完成20次访谈,使用NVIVO软件进行反思性主题分析。

主要发现

  • 识别出的最佳实践包括从开始即参与、面对面沟通、完整反馈闭环、同级伙伴、结构化参与和指南、建立共同目标、患者教育与赋权、建立信任与平衡。
  • 这些活动可通过利益相关者之间的深度合作来实施。
  • 根据所有利益相关者群体的意见构建了患者参与的定义,反映所有类型患者在决策过程所有层面的参与。

临床怎么用

  • 在药物警戒中推动患者参与时,可参考从开始即参与、面对面沟通、完整反馈闭环、同级伙伴、结构化参与和指南、建立共同目标、患者教育与赋权、建立信任与平衡等最佳实践。
  • 通过利益相关者之间的深度合作来实施患者参与活动。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Involving patients in decision making adds value in the context of pharmacovigilance (PV). This added value goes beyond participation in spontaneous reporting systems for adverse drug reactions. However, there is a gap between allowing patients to report and actual patient involvement. Views regarding best practices from regulators, patient organizations and pharmaceutical companies could help increase and improve patient involvement in PV. OBJECTIVE: The aim of this study was to investigate the factors contributing to best practices for patient involvement in PV and to develop a definition of patient involvement based on a qualitative multistakeholder study across Europe. METHODS: A literature review was conducted to map the field of study and obtain insights for the elaboration of an interview guide. Subsequently, patient representatives, members of the pharmaceutical industry and regulators were invited to participate in interviews. These interviews were analyzed using NVIVO® software and employing reflective thematic analysis. RESULTS: A total of 20 interviews were conducted with representatives at both the national and European levels. The best practices identified were engagement from the start, face-to-face communication, a full circle of feedback, same-level partners, structured involvement and guidelines, establishing common goals, patient education and empowerment, and developing trust and balance. These activities can be implemented via deep collaboration among stakeholders. A definition of patient involvement was constructed in accordance with the input of all stakeholder groups, which reflects the involvement of all types of patients at all levels of the decision-making process. CONCLUSION: In this study, we developed a definition for patient involvement based on qualitative interviews. The factors contributing to best practices for patient involvement were mentioned across stakeholder groups and aimed to stimulate patient involvement in PV. Patients are eager to become equal partners and to engage effortlessly in the same manner as other stakeholders.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. van Hoof M, Chinchilla K, Härmark L, et al. Factors Contributing to Best Practices for Patient Involvement in Pharmacovigilance in Europe: A Stakeholder Analysis. Drug Saf. 2022. PMID: 36008634. doi:10.1007/s40264-022-01222-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。